Eris Lifesciences Ltd. share price target

Eris Lifescience (ERIS) delivered slightly better-than-expected revenue for the quarter. However, EBITDA/PAT were marginally below our estimates (4%/6% miss).

up 12.5% YoY). Though 9MFY26 revenue growth (up 8% YoY) was muted, we from human insulin market. Eris has opted for inorganic route to diversify and scale up existing portfolio. This has been implemented without diluting margins. We expect margins to scale up from the current level of 36% in FY26...

Sales/EBITDA/APAT reported 2%/-1.5%/2.3% above our estimates. EBITDA Margin reported 110 bps below our estimates

Eris Lifesciences (ERIS) reported lower-than-expected performance with a 4%/8%/11% miss on revenue/EBITDA/PAT for the quarter. ERIS witnessed strong growth in the international business.

Sales/EBITDA/PAT reported 1%/3%/0.1% above our estimates. EBITDA margin reported 80 bps above our estimates at 36.4%

Eris Lifesciences (ERIS) reported in-line revenue/EBITDA for the quarter. However, there was a slight miss on earnings due to higher interest costs and tax rate for the quarter.

Domestic business margin increased by 37.5% and Biocon's margin by 1100 bps to 30%. Consol EBITDA margin at 35.8%

Eris Lifesciences' (ERIS) Q1FY26 EBITDA was broadly in line with our estimate (Rs2.75bn; up 11% YoY). Though Q1FY26 revenue growth (up 7.4% YoY) was muted, we see pick up in coming quarters as insulin shortages stabilize, export pick up and likely additional market share gain from human insulin market. Eris has opted for inorganic route to diversify and scale up existing portfolio. This has been implemented without diluting margins. We expect margins to scale up from the current level of 35% in FY25 as revenue scales up from recent...

Strong FY26 guidance with +15% revenue growth with 36% OPM. up 70% YoY). Eris has opted for inorganic route to diversify and scale up expect margins to scale up from the current level of 35% as revenue scales up from recent acquisitions, which are currently operating at sub-optimal profitability. The company has multiple growth levers such as broad-based...

Eris Lifesciences (ERIS) posted lower-than-expected 4QFY25 performance. This has been largely due to a marginal slip in the execution, particularly in the insulin revenue.

Base domestic growth at 12% vs IMP growth of 8% due to new product launches and price increase

Eris Lifescience’s (ERIS) 3QFY25 performance came in below our estimates. Lower-than-expected revenue growth led to lower operating leverage, which affected the overall performance.

Q2 revenue/PAT above our estimates due to better traction in both base and acquired businesses

ERIS posted strong revenue performance in Q4 with a beat of 8%, but EBITDA came below BBG consensus due to higher opex and one-offs

Harnessing Growth Through Strategic Acquisitions